Jean Marc S. D. C.
- Country
- France
- Department
- Hematology
Research Overview
- A Study of CC-122 in Patients with Multiple Myeloma, Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma
- Dose Optimization and Safety Evaluation of ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
- Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Data & Insights
Has run more than one trial at 196 of 349 partner sites.
Specializations
Multiple Myeloma Research
Primary focus on investigating novel therapeutic approaches for multiple myeloma, including both newly diagnosed and relapsed/refractory cases. Extensive experience with targeted therapies and combination treatments.
- Newly Diagnosed Multiple Myeloma (NDMM)
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Post-Transplant Maintenance Therapy
Specializes in evaluating innovative treatment combinations and maintenance strategies for multiple myeloma patients.
Lymphoma Studies
Significant involvement in research targeting various forms of B-cell lymphomas and T-cell lymphomas, with particular emphasis on novel therapeutic approaches.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- MALT Lymphoma
- Advanced T-Cell Lymphomas
Focuses on developing treatment strategies for both aggressive and indolent lymphomas.
Innovative Therapies
Leads investigations into novel therapeutic agents and their combinations, including monoclonal antibodies and emerging treatment modalities.
- Targeted Immunotherapy
- Combination Treatment Strategies
- Maintenance Therapy Optimization
Specializes in evaluating treatment efficacy and safety profiles of innovative therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.